For HER2-mutant NSCLC, Zongertinib (a TKI) is now the first-line choice. While TKIs show activity after ADCs like TDXD, the effectiveness of using an ADC after TKI failure remains an unproven but critical clinical question for oncologists.
Given the risk of interstitial lung disease (ILD) with TDXD, clinicians should consider a baseline pulmonology consult for NSCLC patients with pre-existing lung issues. This proactive step helps establish a baseline and can prevent mismanaging potential adverse events.
Though TROP2 antibody-drug conjugates share a mechanism, their adverse event profiles differ significantly. Datopotamab-deruxtecan commonly causes stomatitis, while Sacituzumab govitecan is associated with high rates of neutropenia, necessitating drug-specific management.
Clinicians can confidently reduce the dose of Datopotamab-deruxtecan to manage toxicity. Phase 1 data demonstrates a compelling efficacy signal even at a 4 mg/kg dose level, reassuring oncologists that dose reduction is a viable strategy to maintain treatment without sacrificing benefit.
In NSCLC, "HER2 positive" can mean one of three largely separate conditions: rare exon 20 mutations (~2%), rare gene amplifications (~2%), or more common protein overexpression (20-30%). Understanding these distinctions is critical for accurate biomarker testing and selecting appropriate therapies.
When evaluating data like the impressive results from the SAC-TMT trial, clinicians must consider its geographic context. The study was conducted only in China, where trial outcomes are often more favorable than in broader global populations, warranting cautious optimism while awaiting global data.